Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including the world's first clinical trial of conditionally immortalised neural stem cell therapy for stroke disability, the company has pivoted to…
In vivo cell reprogramming therapies for degenerative disease
Mogrify is a biotechnology company developing a novel class of in vivo reprogramming therapies for degenerative diseases. Its proprietary platforms use large-scale transcriptomic and epigenomic network data to predict the transcription factors required to convert mature human cells directly into target therapeutic…
Single-use bioprocess solutions supplier for life sciences
BioPharma Dynamics is a supplier of single-use bioprocess solutions for the life sciences and pharmaceutical industries. The company sources products from multiple market-leading manufacturers rather than tying customers to a single supplier range. Its portfolio spans hose and tubing, transfer sets, bags, fittings,…
Global CDMO for drug development, delivery and manufacture
Catalent Pharma Solutions is a contract development and manufacturing organisation providing drug development, formulation, and manufacturing services across small molecules, biologics, cell and gene therapies, and consumer health products. The company offers proprietary drug delivery platforms including its orally…
Programmable RNA for scalable cell engineering and biomanufacturing
Plurify is a biotechnology company developing PluRNA, a programmable RNA platform for sustained protein expression without genome integration. Its technology is designed to engineer cells through controllable RNA-based programmes, with applications in stem-cell therapy manufacturing, cell purification, biologics…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic switch that keeps engineered T-cells dormant in healthy tissue and activates them only within the low-oxygen environment typical of solid…
Next-generation viral vectors engineered for safer gene therapy delivery
Sandbox Bioscience is a biotechnology company developing next-generation viral delivery vectors for gene therapy. Founded by a team of virologists with extensive experience in gene therapy delivery systems and platform development, the company is engineering vectors designed to improve on existing market solutions…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Engineered bacterial nanosyringes for intracellular protein delivery
NanoSyrinx is a discovery-stage biotechnology company developing a platform for targeted intracellular delivery of protein and peptide therapeutics. Based on naturally occurring bacterial nanomachines, the company's technology is engineered to deliver biological payloads directly to the cytosol of targeted cells…
Technology innovation centre for process scale-up and manufacturing
CPI is a UK innovation centre and social enterprise that helps companies develop, scale and commercialise new products and processes across pharmaceuticals, bioprocessing, health technology and sustainable manufacturing. As a founding member of the High Value Manufacturing Catapult, CPI provides access to specialist…
Gene therapy biotech targeting neural circuit dysfunction
Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits. Its approach combines precision AAV delivery to selected neural circuits with tuneable neuromodulation, using human iPSC-derived neural models to direct the evolution of human-centric…
Automated manufacturing platform for cell and gene therapy production
Oribiotech is a UK-based developer of an automated manufacturing platform for cell and gene therapies. Its technology combines proprietary hardware, consumables, software and analytics to close, standardise and scale CGT production, enabling therapeutics developers to move from pre-clinical process development through…
Reprogrammed stem cell therapies for vascular disease and chronic wounds
ReproGo is a Belfast-based regenerative medicine company developing Advanced Therapy Medicinal Products through direct cell reprogramming of adult cells into vascular lineages. The company's manufacturing approach produces stem cell-derived vascular cells and organoids through a xeno-free, low-dose process designed…
Approved presbyopia eye drops and investigational retinal therapies
Tenpoint Therapeutics is an ophthalmic biopharmaceutical company developing medicines and regenerative cell therapies for age-related vision disorders. Its dual-agent carbachol/brimonidine eye drops received US FDA approval for presbyopia in January 2026 and became commercially available in March. A UK regulatory…
UK national innovation centre for cell and gene therapy
Cell and Gene Therapy Catapult is a UK independent innovation organisation established to advance the cell and gene therapy industry by bridging the gap between research and commercial scale. It operates GMP-compliant Manufacturing Innovation Centres in Stevenage and Braintree, offering process development, technology…
Specialist AAV vector manufacturer for gene therapy developers
Trisk Bio is a contract development and manufacturing organisation specialising in the production of adeno-associated virus vectors for gene therapy applications. Its intensified manufacturing processes use suspension bioreactors and chromatography-based purification to deliver high-purity AAV at scalable yields for…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people worldwide for which no disease-modifying treatment currently exists. Its lead programme, Rincell-1, is an otic neural progenitor cell therapy…
Full-service CRO for Phase I–IV pharmaceutical and device trials
Clinicology is a contract research organisation providing clinical trial management services to pharmaceutical, biotechnology, and medical device companies. Services span site startup, monitoring, project management, regulatory submissions, patient recruitment, medical monitoring, medical writing, and…